• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Nature >BNT162b2-eIicited neutralization of B.1.617 and other SARS-CoV-2 variants
【24h】

BNT162b2-eIicited neutralization of B.1.617 and other SARS-CoV-2 variants

机译：Bnt162b2-Eiicited中和B.1.617和其他SARS-COV-2变体

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is continuing to evolve around the world, generating new variants that are of concern on the basis of their potential for altered transmissibility, pathogenicity, and coverage by vaccines and therapeutic agents~(1-5). Here we show that serum samples taken from twenty human volunteers, two or four weeks after their second dose of the BNT162b2 vaccine, neutralize engineered SARS-CoV-2 with a USA-WA1/2020 genetic background (a virus strain isolated in January 2020) and spike glycoproteins from the recently identified B.1.617.1, B.1.617.2, B.1.618 (all of which were first identified in India) or B.1.525 (first identified in Nigeria) lineages. Geometric mean plaque reduction neutralization titres against the variant viruses-particularly the B.1.617.1 variant-seemed to be lower than the titre against the USA-WA1/2020 virus, but all sera tested neutralized the variant viruses at titres of at least 1:40. The susceptibility of the variant strains to neutralization elicited by the BNT162b2 vaccine supports mass immunization as a central strategy to end the coronavirus disease 2019 (COVID-19) pandemic globally.
机译：严重急性呼吸综合征冠状病毒2（SARS-COV-2）继续在世界各地发展，产生新的变体，这些变体是基于其改变传播性，致病性和疫苗和治疗剂覆盖的潜力的潜力〜（1 -5）。在这里，我们显示血清样本从二十人志愿者服用，第二种剂量在第二剂BNT162B2疫苗后，用USA-WA1 / 2020遗传背景（2020年1月孤立的病毒菌株）中和工程的SARS-COV-2来自最近鉴定的B.1.617.1，B.1.617.2，B.1.618（所有在印度鉴定的B.1.617.2，B.1.525（首次在尼日利亚确定）谱系中的穗糖蛋白。几何平均斑块还原滴度抵抗变体病毒 - 特别是B.1.617.1变体 - 似乎低于USA-WA1 / 2020病毒的滴度，但所有血清都在滴度中和至少1的滴度中和变体病毒：40。通过BNT162B2疫苗引发的变异菌株与中和的敏感性支持大规模免疫作为终止冠状病毒疾病2019（Covid-19）大流行的中央策略。

著录项

  • 来源
    《Nature》 |2021年第7871期|273-275|共3页
  • 作者

    Jianying Liu; Yang Liu; Hongjie Xia; Jing Zou; Scott C Weaver; Kena A Swanson; Hui Cai; Mark Cutler; David Cooper; Alexander Muik; Kathrin U Jansen; Ugur Sahin; Xuping Xie; Philip R Dormitzer; Pei-Yong Shi;

  • 作者单位

    Department of Microbiology and Immunology University of Texas Medical Branch|Institute for Human Infections and Immunity University of Texas Medical Branch;

    Department of Biochemistry and Molecular Biology University of Texas Medical Branch;

    Department of Biochemistry and Molecular Biology University of Texas Medical Branch;

    Department of Biochemistry and Molecular Biology University of Texas Medical Branch;

    Department of Microbiology and Immunology University of Texas Medical Branch|Institute for Human Infections and Immunity University of Texas Medical Branch|Institute for Translational Sciences University of Texas Medical Branch|Center for Biodefense and Emerging Infectious Diseases University of Texas Medical Branch|Sealy Institute for Vaccine Sciences University of Texas Medical Branch;

    Pfizer Vaccine Research and Development;

    Pfizer Vaccine Research and Development;

    Pfizer Vaccine Research and Development;

    Pfizer Vaccine Research and Development;

    BioNTech;

    Pfizer Vaccine Research and Development;

    BioNTech;

    Department of Biochemistry and Molecular Biology University of Texas Medical Branch;

    Pfizer Vaccine Research and Development;

    Institute for Human Infections and Immunity University of Texas Medical Branch|Department of Biochemistry and Molecular Biology University of Texas Medical Branch|Institute for Translational Sciences University of Texas Medical Branch|Center for Biodefense and Emerging Infectious Diseases University of Texas Medical Branch|Sealy Institute for Vaccine Sciences University of Texas Medical Branch;

  • 收录信息 美国《科学引文索引》(SCI);美国《工程索引》(EI);美国《生物学医学文摘》(MEDLINE);美国《化学文摘》(CA);
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类
  • 关键词

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号